Ординатура / Офтальмология / Английские материалы / Ocular Therapeutics Eye on New Discoveries_Yorio, Clark, Wax_2007

514

INDEX

Pegaptanib, 24, 354, 373, 449,

haze following see Corneal

487

opacity (haze), post-

Pemirolast, 207

refractive surgery

Penems, 324

Physical gene transfer meth-

Penetration enhancement, 11

ods, 398

D-Penicillamine, 349

Physostigmine, 50

Penicillin, 18, 321, 324, 326

Pigment epithelium-derived

microbial resistance, 322

factor, 71, 79, 374, 379,

Penicillin G, 306

486

Peptide antibiotics, 325, 326,

anti-angiogenic activity, 102,

369–370

404

Perennial allergic conjunctivi-

ciliary body expression, 79

tis, 204, 207, 239, 240,

delivery systems, 106

242, 247

intravitreal, 24

Perfluorohexyloctane, 355

gene therapy, 404, 408, 463

Perfluoropropane gas, 343

retinal neuroprotection, 104,

Peripheral ulcerative keratitis,

106, 458

221–222

vascular endothelial growth

treatment, 222–223

factor antagonism, 102

Peripherin, 445

Pigmented ciliary epithelium,

Pheniramine, 243

47, 69–70

Phenylephrine, 308

aqueous humor production,

Phenytoin, 427

70

Phospholipase C, 215

retinal stem cells, 80

Photodynamic therapy, 348

Pili, 215

age-related macular degen-

Pilocarpine, 9, 17, 18, 49, 50, 127

eration, 353, 449

Piperacillin, 322

choroidal neovascularization,

Pirenzepine, 177, 186, 188

485

Pituitary adenylate-cyclase-

posterior capsule opacifica-

activating peptide, 78

tion following cataract

Placental growth factor

surgery prevention, 350

1, 479

Photoperiod

vascular endothelial growth

myopia associations, 181–182

factor regulation, 103

refractive development influ-

Plasmin, vitreous removal,

ence, 173–174

381–382, 384

retinal dopamine metabo-

Plasminogen kringle 5, gene

lism, 181

therapy, 404

Photoreceptors

Platelet activating factor, 205

apoptosis in degenerative

Platelet-derived growth fac-

retinopathies, 446, 447

tor, 88

gene delivery methods, 395,

angiogenesis, 480–481

396

aqueous humor, 96

neuroprotective gene ther-

corneal expression, 95–96

apy, 406

corneal myofibroblast

transplantation, 444–445, 450,

differentiation, 137

451–452

corneal wound healing, 135,

Photorefractive keratectomy,

335

133, 336

diabetic retinopathy, 103

corneal wound healing,

isoforms, 95

135–136, 335

lacrimal gland production,

myofibroblast

109

differentiation,

ocular cicatricial

136–137

pemphigoid, 222

INDEX

white dot syndromes, 304

Protegrins, 369

Posterior vitreous detachment,

Protein kinase C, 74, 93, 405

379–381

Protein kinase C inhibitors,

enzymatic induction

53–54

see Vitreolysis,

Protein kinase inhibitors,

pharmacological

intraocular pressure

Post-operative scarring,

lowering agents, 53–54

333–334

Protein synthesis, antibiotic

Posurdex(R), 8, 25, 26, 313

targets, 323, 326

Prednisolone, 18, 208, 231, 254,

Proteomics, trabecular mesh-

259, 307, 368

work in glaucoma, 61

Prednisone, 223, 227, 280, 292,

Protozoan infection, 318

309, 310, 351

Pseudogerontoxon, 252

Presbyopia

Pseudomonas aruginosa, 214, 215,

age-related cortical cataract

216

risk, 158

antibiotic resistance, 324

age-related lens changes,

vaccines, 328

152–153

virulence factors, 215

Prinomastat, 354, 357

Psoriatic arthritis, 224, 278

Prodrug preparations

Pterygium, postsurgical recur-

intravitreal delivery, 25

rence prevention, 349

non-steroidal anti-inflamma-

Pulsed drug delivery, 10–11, 16

tory drugs, 368

subretinal microchip sys-

prostaglandin analogs, 49

tems, 29

topical delivery, 19

transscleral, 23

Progesterone, 75

Punctal inserts, 19

Prohormone convertases,

Punctal plugs, 212

71, 72

Punctate epithelial keratitis

Proliferative cell nuclear anti-

atopic keratoconjunctivitis,

gen, 357

257

Proliferative vitreoretinopathy,

vernal keratoconjunctivitis,

334, 354–357, 474

252

antiproliferative agents,

Punctate inner choroidopathy,

355–356

304

cellular motility modulators,

Punctum, drug delivery to tear

357

film, 19

extracellular matrix remod-

Pyrazinamide, 306

eling, 357

Pyrimethamine, 306

gene therapy, 401

growth factor modulators,

R

356–357

Radiation

Propionibacterium acnes, 303

posterior subcapsular cata-

Prostaglandin analogs

ract risk, 150, 160

continuous delivery systems,

postoperative β irradiation,

11

348, 349

intraocular pressure lowering

subretinal space implants, 29

agents, 49

Ragweed allergens, 204, 205,

Prostaglandin D2, 205

206, 240

Prostaglandin D2 synthase, 76

Ranalexin, 369

Prostaglandin receptor ago-

Ranibizumab, 24, 105, 313, 354,

nists, 49

373, 403, 449, 487

Prostaglandins, 286–287,

Rapamycin, 29, 262

290–291

Rare retinal degenerations, 444

allergic conjunctivitis, 241

cell biology, 446

516

INDEX

Retina (continued)

insulin-like growth factor,

refractive development

481–482

integration, 174

retinopathy of prematurity,

Retinal detachment

482

atopic keratoconjunctivitis,

vascular endothelial growth

204, 258

factor, 479

myopia, 169

Retinal pigment epithelium

posterior vitreous

apoptosis in age-related mac-

detachment, 380

ular degeneration, 447

surgical repair, 378

cell transplantation, 452–453

viral posterior segment

development, 69

uveitis, 303

gene transfer methods, 395,

vitreous syneresis, 379

396, 398

Vogt Koyanagi Harada syn-

growth factor support, 101

drome, 304

Retinal progenitor stem cells,

Retinal electronic prosthetic

79–80

implant, 28, 455–457

Retinal tears

Retinal ganglion cells, 4, 5

iatrogenic, 380, 381

gene transfer methods, 396,

vitreous syneresis, 379

398

Retinal vein occlusion, 11, 25

glaucomatous neuropathy,

retinal/choroidal

423–424

neovascularization, 102

pressure-related axonal

Retinal vessels, 474–475

transport blockade, 424,

development, 475–477

425

astrocyte meshwork

secondary degeneration,

template, 476–477

424

hypoxia-inducible factor

growth factor support, 101–

1, 476

102, 104–105, 424–425

oxygen regulation, 475–476

optic nerve head axonal

remodeling, 477

transport, 106–107

Retinitis pigmentosa, 443–444

neuroprotective gene ther-

cell biology, 446

apy, 406, 407–408

inner retinal neuron pres-

neuroprotective strategies,

ervation, 450

423, 424

clinical features, 444

anti-apoptotic therapy,

Encapsulated Cell

429–432

Technology, 460

free radicals deactivation,

gene therapy, 395, 399, 445,

428–429

464

glutamate excitotoxicity

genetic basis, 444, 445

blockade, 425–428

Wnt signaling

heat shock protein 70,

abnormalities, 101

432–434

intravitreal ciliary

immune mechanisms,

neurotrophic factor

435–436

delivery, 26

nitric oxide inhibition,

molecular biology, 445

428–429

nutritional therapy, 461–462

Retinal necrosis syndrome,

omega-3 fatty acids, 448

acute, 303

vitamin A, 447–448, 461

treatment, 306

recent developments,

Retinal neovascularization, 482

450–466

growth factor involvement,

cell transplantation, 399,

102–103

450, 451–455

INDEX

s-Flt, 404

Syk kinase inhibition, 246

Salmosin, 352

transforming growth factor β

Sarcoidosis, 225, 278, 304, 311

receptor blockade, 337,

Scar formation, 334

346–348

Schlemm’s canal, 47, 405

viral vector delivery, 403

aqueous humor outflow, 70

Smoking, 209

cytoskeletal elements, 51–52

age-related macular degener-

glaucoma-related

ation risk, 444, 446–447

changes, 48

age-related nuclear cataract

Scleral patch, 458–459

risk, 154–155

Scopolamine, 308

passive, myopia association,

Seasonal allergic conjunctivitis,

178–179

204, 206, 207, 239, 240,

Smurf-1, 108

242, 247

Smurf-2, 108

Secretoneurin, 77

Sodium nitrite, 58

Secretory component, 200

Sodium nitroprusside, 58

Secretory immunoglobulin A,

Soemmering’s cataract, 350

200, 201

Somatostatin, 185

tears, 210

aqueous humor, 201

Selectin, 61

ciliary epithelium expression,

Self-tolerance, 283–284

71, 72

Serotonergic agonists,

Somatostatin analogs, 338

intraocular pressure

Soothe(TM), 121

lowering agents, 55–56

Sorsby’s fundus dystrophy, 461

Serpiginous choroiditis, 304,

Spiradoline, 58

310

Spondyloarthropathy, uvei-

Serum amyloid A, 61

tis association, 224,

Sex steroids, ciliary body

277–278

synthesis, 75

Spray drug delivery, 18–19

Sickle cell disease, 403

Squlamine lactate, 463

Siloxane polymers, 15

Staphylococcus aureus, 318, 319

Sirolimus, 29

Staphylococcus epidermidis, 214

Sj”gren’s syndrome, 127

Stargardt disease, 444, 445, 447,

keratoconjunctivitis sicca,

450, 460, 464

120, 122, 211

gene therapy, 466

lacrimal gland dysfunction,

genetic basis, 445

211

Statins, 54–55

meibomian gland dysfunc-

Stem cell transplantation,

tion, 211

453–454

Smad signaling, 95, 109, 348,

Steroid responders, 280, 308,

353, 356

309

Smads, 92

Steroid therapy see

therapeutic targets, 348, 353

Corticosteroids

Small interfering RNAs

Stevens–Johnson syndrome,

(siRNAs), 11

222

age-related macular degen-

Strabismus surgery, 339

eration, 464

post-operative scarring, 334

anti-vascular endothelial

postoperative adherence syn-

growth factor, 105, 354

dromes, 339

carbonic anhydrase gene

antiproliferative agents,

targets, 406

339

choroidal neovascularization,

physical barriers, 339

403

Streptokinase, 381

518

INDEX

T

uveitis, 225, 228, 286

T cell-mediated responses, 200

Th2 helper cells, 283, 285

atopic keratoconjunctivitis,

allergic conjunctivitis,

261

241–242

bacterial keratitis, 215–216

bacterial keratitis, 215, 216

conjunctivitis

Theratears(TM), 120

allergic, 205–206

Thiotepa, 349

giant cell, 261

Thyroid-associated orbitopa-

corneal allograft rejection,

thy, 338

229–230

Tie1, 481

dry eye syndromes, 210–211

Tie2, 103, 481

herpes simplex keratitis, 219

Tigecycline, 321

T cells

Timolol, 17, 49, 279, 427

anterior chamber-associated

Tissue inhibitors of matrix met-

immune deviation,

alloproteinases, 99

201–202

Tissue plasminogen activator,

cytokine production, 285

381

immune-mediated ocular

drug delivery systems, 18,

disease, 284–285

24, 28

neuroprotective activity,

glaucoma postoperative

435–436

management, 347

see also CD4 T cells; CD8 T

posterior vitreous detach-

cells; Cytotoxic T cells;

ment induction, 381

Th1 helper cells; Th2

Tissue repair, 333–358

helper cells

Tissue-selective drug activity,

Tachyplesins, 369

11

Tacrolimus, 260, 262, 311

Tobramycin, 18, 325, 326

Tamoxifen, 153

Toclizumab, 295

Targeting, drug delivery

Toll-like receptors (TLRs), 281,

systems, 10, 11–12

282

Taxol, 349

Topical drug delivery systems,

Tear film, 209, 210

13, 16–21, 370–372

allergic conjunctivitis, 241

anterior objective, 16–19

epidermal growth factor, 94

posterior objective, 19–21

hepatocyte growth factor,

Topical reservoir inserts, 7

94–95

Toxocara canis, 225, 303

keratinocyte growth factor,

Toxoplasma gondii, 225

94–95

Toxoplasmosis, 225, 227

Tear film stabilizers, 120–121

retino-choroiditis, 302

Tear supplements, 120

treatment, 306

Tears

Trabecular meshwork, 47

essential fatty acids, 213

aqueous outflow, 47, 70

production stimulation, 127

cytoskeletal elements, 51–52

secretory immunoglobulin A,

extracellular matrix

200, 210

accumulation with

Testosterone, 129

glaucoma, 48, 97

Tetracyclines, 212, 318, 323, 324,

gene therapy with tissue

325, 326

specific promoters, 409,

microbial resistance, 322, 323

410

Tetrahydrocannabinol, 59

growth factor expression,

Tetrodotoxin, 186

60–61, 97–100

Th1 helper cells, 284

bone morphogenetic

bacterial keratitis, 215–216

proteins, 98–99

herpes simplex keratitis, 219

interleukins, 99–100